Between Jan 2017 till Dec 2020, 100 consecutive HCC with PVT patients (pt) were accrued [male 97(97%), CP A 66%, CP B 30%, mean age 61.4 years (38-77yrs), CLIP 0-2: 29 (29%), CLIP 3-6 69 (69%), infective etiology 10%, PS0-1 81% ]. In 100 consecutive patients accrued, 70 were evaluable for response assessment (>3 mo follow up). Mean survival was 7.91 mo (3 mo-30 mo), 54 patients expired and 41 were alive. 28 (40%) patients had recanalization of PVT (response), 36 (51%) pts did not recanalize, 3 (4%)pt had progressive disease and 3 (4%) did not have response evaluation. Mean overall survival in responders and non-responders were 10.57 and 6.47 month respectively (p-0.001). Mean survival in patients with PS0, PS1 and PS2 were 16.5, 11 and 10.1 mo (p-0.039) respectively. Alcohol intake had a trend towards significance (9.3 Vs 14.6 mo; p-0.089). Adjuvant sorafenib, BCLC stage, gender, age, RT dose did not influence response to treatment. Among these 70 evaluable pts, 17pt (24%) had RILD [6 (8%) had Classic RILD & 11 (16%) had non-classic RILD]. CP score assessment at 2 month follow up, 38 (54%) had no change in CP score. Decline of 1, 2 & 3 point CP score from baseline was in 9 (13%), 12 (17%), 13 (19%) pts. Improvement in CP score from baseline in 7(10%). Among 100 patients who underwent fiducial placement, decompensation occurred in 15 patients (15%), 5(5%) had post-fiducial bleed and 1 patient (1%) required embolization. At Post-CK3 month decline from Grade A to B in 20 (28%) and C in 2 (2%). Decline from grade B to C in 4 (6%).